Aeolus Pharmaceuticals, Inc. is a biopharmaceutical company developing its compound, AEOL-10150, as a treatment for the lung effects of acute radiation syndrome (Lung-ARS). AEOL-10150 is catalytic antioxidant compound based on technology developed at Duke University and National Jewish Health. These compounds, known as metalloporphyrins, scavenge reactive oxygen species at the cellular level, mimicking the effect of the body’s own natural antioxidant enzyme superoxide dismutase. The Company’s products include AEOL 10150, AEOL 11207, and ED-Customer.com. It also has two programs underway for the development of its second drug candidate, AEOL 11207, for the treatment of epilepsy and Parkinson’s disease. Its AEOL 10150 product includes catalytic antioxidant program, which is designed to retain the catalytic mechanism and high antioxidant efficiency of the natural enzymes and create and develop stable and small molecule antioxidants without the limitations of superoxide dismutase.